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Five  New  Sch izophren ia  Loci M ay  Converge  on  
the  Sam e  Ce llu lar M echan ism : The  A KT Pathw ay
To the Editor: The complexity of schizophrenia genetics 
raises new questions regarding the biological plausibility of 
findings from association studies (1). Is there a shared cellular 
mechanism for the diverse proteins encoded by the dozens 
of “schizophrenia genes”? The Schizophrenia Psychiatric Ge-
nome-Wide Association Study Consortium reported signifi-
cant associations for five new gene loci (2). Here, we show that 
these loci are all associated with the neuregulin-1-induced 
activation of the phosphatidylinositol 3-kinase/protein ki-
nase B/AKT1 intracellular system, which is an important 
convergence point for several putative factors of psychotic 
disorders including biogenic amines, synaptic proteins, and 
growth factors (3, 4). Decreased AKT1 protein levels and 
phosphorylation have been documented in lymphocytes and 
brains of individuals with schizophrenia (4–6). We genotyped 
115 healthy volunteers for the following five loci: MIR137, 
PCGEM1, CSMD1, MMP16 (also associated with cancer), and 
CNNM2 (a metal ion carrier) (2). The AKT1 pathway, similarly 
to four of the five loci, is implicated in cell proliferation and 
differentiation. AKT1 activation was determined from pe-
ripheral lymphoblasts by using an immunoblot assay (5, 6). 
We also studied the extracellular signal-regulated kinase ki-
nase (MEK-) extracellular signal-regulated kinase (ERK) path-
way. Results revealed that the ratio of phosphorylated AKT1 
(Ser473; 60 kDa) to total AKT1 was lower in risk-allele carriers 
(mean ratio averaged across the five foci, 0.21) relative to non-
carriers (mean ratio, 0.39). This result was evident for all five 
foci (p<0.001 in all cases; Table 1). We did not observe similar 
changes in the case of ERK ratios. Our findings raise the pos-
sibility that the complex array of proteins encoded by “schizo-
phrenia genes” converge on common intracellular molecular 
pathways that convert information from the environment to 
the biological system.
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TA BLE  1 . A K T  and  Ex trace llu la r S igna l-Re gu la ted  K inase  (ERK ) A c tiv a tion  Re la tive  to  the  R isk  A lle le s o f  F ive  New  
Sch izoph ren ia  Lo c ia
Gene
Chromo-
some
Single-
Nucleotide 
Polymor-
phism Alleles N (Risk)
Risk-Allele 
Carriers 
pAKT/AKT
Noncarriers 
pAKT/AKT
Mann-Whitney 
Test (AKT Ratio)
Risk-Allele 
Carriers 
pERK/ERK
Noncarriers 
pERK/ERK
Mean SD Mean SD Z p Mean SD Mean SD
MIR137 1p21.3 rs1625579 TG 95 0.22 0.15 0.45 0.11 –5.45 <0.0001 0.38 0.19 0.37 0.17
PCGEM1 2q32.3 rs17662626 AG 105 0.27 0.13 0.53 0.17 –3.37 0.0001 0.41 0.12 0.43 0.16
CSMD1 8p23.2 rs10503253 AC 69 0.26 0.14 0.36 0.14 –3.41 0.0007 0.40 0.14 0.44 0.14
MMP16 8q21.3 rs7004633 GA 18 0.14 0.15 0.32 0.14 –3.94 0.0001 0.36 0.13 0.36 0.11
CNNM2 10q24.32 rs7914558 GA 19 0.16 0.15 0.29 0.13 –3.39 0.0007 0.37 0.19 0.35 0.12
a The table shows data from 115 healthy volunteers of Central-Eastern European descent with a negative family history for schizophrenia and 
major mood disorders (mean age=45.6 years, SD=8.7; mean education=12.4 years, SD=4.8; 57 female participants). Genotyping was per-
formed using a TaqMan assay (Applied Biosystems, Foster City, Calif.; duplicate run, error rates <2%; no deviation from the Hardy-Weinberg 
equilibrium). In alleles, the first one is the risk allele from stage 1 of the genome-wide association study (1). “N (Risk)” refers to the number 
of participants with the risk allele. Means and standard deviations for the ratios of neuregulin-1-induced phosphorylated AKT and ERK (pAKT 
and pERK) and total AKT and ERK are shown in the case of risk-allele carriers and noncarriers. Groups were compared with Mann-Whitney U 
tests. In the case of pERK/ERK ratios, risk-allele carriers and noncarriers did not differ (p>0.5 in all cases).
